Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJH3U0)

• Drug Name: TAK-659 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Phase 2	[1]
Haematological malignancy	2B33.Y	Phase 1/2	[2]

• Cross-matching ID:
  PubChem CID: 53252276
  CAS Number: CAS 1312691-33-0
  TTD Drug ID: DMJH3U0

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostamatinib	DM6AUHV	Immune thrombocytopenic purpura	3B64.13	Approved	[4]
Fostamatinib disodium	DM3274D	Thrombocytopenia	3B64	Phase 3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[6]
GS-9876	DM9Q2B6	Cutaneous lupus erythematosus	EB5Z	Phase 2	[7]
GS-9973	DMKWCTR	Acute myeloid leukaemia	2A60	Phase 2	[8]
Cevidoplenib	DM9QU5G	Rheumatoid arthritis	FA20	Phase 2	[9]
HM43239	DMV1SDA	Acute myeloid leukaemia	2A60	Phase 1/2	[10]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[11]
SKI-O-703	DMTSKXR	Rheumatoid arthritis	FA20	Phase 1	[7]
PRT6207	DMP5CLY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[13]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[15]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[16]
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[17]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[18]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[13]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[1]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[19]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02323113) Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
• [3] J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Company report (Portola Pharmaceuticals)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
• [9] A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
• [10] Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
• [11] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [12] Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [16] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [17] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [19] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
• [20] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.